By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    medicare part d benefits
    Everything that You Need to Know About Medicare Part D
    August 15, 2022
    Best Ways to Boost Your Immune System this Winter
    Best Ways to Boost Your Immune System this Winter
    November 15, 2022
    back pain issues
    Ways to Treat Constant Back Pain
    August 21, 2023
    Latest News
    How Probate Planning Shapes the Future of Your Estate and Family Care
    July 17, 2025
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    More On Wellness Programs To Improve Health and Reduce Costs
    January 25, 2012
    Privatizing Social Security and Medicare: Who Can Defuse Political Dynamite?
    June 12, 2011
    Study: Risk of Death in Elderly Patients with Dementia Doubled with Some Antipsychotic Medications
    February 26, 2012
    Latest News
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
    How Health Choices and Legal Actions Intersect After an Injury
    July 17, 2025
    How communities and healthcare providers can address slip and fall injuries with legal awareness
    July 17, 2025
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Finance > Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials
BusinessFinanceSpecialties

Startup Alzheon’s Proposal for Alzheimer’s Drug Success Adds New Science to Failed Trials

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
SHARE

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials.

alzheon alzheimer's drugFirst published on MedCityNews.com. From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage trials. For startup Alzheon, though, those failures have left behind a trail of valuable clinical and biomarker data that it thinks could lead to hidden treasure.

Alzheon launched today with a plan to scoop up abandoned drug candidates to which it thinks it can apply recent advances in the understanding of Alzheimer’s disease and new diagnostic and prognostic tools to refine the drugs and target them toward more specific groups of patients.

For its first clinical candidate, the Lexington, Massachusetts-based biotech has licensed a prodrug of the small molecule tramiprosate from Bellus Health (formerly Neurochem Inc.) of Quebec, Canada. It was designed to inhibit the formation of amyloid assemblies in the brain that experts have long considered characteristic of the disease.

More Read

internet marketing comparison
Website, Social Media, or Email: Where’s Your Real Marketing Muscle?
Health IT Wisdom at the End of 2013 and Start of 2014
Autism On Tape: Using Video To End Dx Delays, Boost Service Access
The Future Of Nursing In A Post-Pandemic World
Evidence Based Care Coordination CAN Work in Medicare

In the late 2000s, Neurochem took the drug as far as Phase 3 studies involving more than a thousand Alzheimer’s disease patients. It failed to meet the trial’s efficacy endpoints.

But in a retrospective analysis of clinical data, researchers found that the drug seemed to slow atrophy of the hippocampus, a kind of brain damage associated with Alzheimer’s, especially in patients with a gene variation called APOE4.

Alzheon will piggyback on those clues and use a prodrug form of tramiprosate, or an inactive substance that is converted into an active drug inside the body. CEO Dr. Martin Tolar said the prodrug has better properties than its parent drug.

Tolar is a neurologist by training and spent six years in leadership positions at Pfizer before taking on roles at various smaller biotech companies including CoMentis Inc., NormOxys and Knome Inc. Working with him on this new venture is former CoMentis and NormOxys colleague John Hey, a 20-year drug development veteran, and Dr. Mark Versavel, who has led neurology projects at Bayer and Pfizer.

The team will use their combined science and business savvy and the existing clinical data behind ALZ-801 to design a Phase 2 efficacy study around specific subpopulations of Alzheimer’s patients who stand to benefit most from the drug. Tolar said the trial should start next year.

While smaller, more targeted trials should in theory be quicker and more likely to produce positive results than large trials, the trials will still be costly. Tolar declined to disclose details of his company’s initial financing but said his team is working with two private investors with a history success in biopharmaceuticals.

As plans for the trial get underway, Alzheon, which was incorporated in August, is also at work building a pipeline. Tolar said the team is in talks with other companies about in-licensing deals that would bring in other therapeutic approaches that have demonstrated safety and proof-of-concept activity in neurodegenerative disease.

Chief Scientific Officer Hey summed up the company’s long-term strategy in a statement: “Alzheon has unique capabilities to deploy our drug development platform and leverage the clinical knowledgebase from past Alzheimer’s programs to deliver the best of both worlds:  innovative treatments for challenging neurodegenerative diseases and well-designed clinical programs that have a high likelihood of success.”

Follow MedCity News on Facebook and Twitter for more updates.

[Image credit: BigStock Photos]

TAGGED:AlzheimersAlzheon
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
How IT and Marketing Teams Can Collaborate to Protect Patient Trust
Global Healthcare Policy & Law
July 17, 2025
paramedics in surgical gloves and masks
How Health Choices and Legal Actions Intersect After an Injury
Health care
July 16, 2025
a woman giving a key
How Probate Planning Shapes the Future of Your Estate and Family Care
Health
July 16, 2025
a woman with kinesio tapes on her back arm
How communities and healthcare providers can address slip and fall injuries with legal awareness
Health care
July 16, 2025

You Might also Like

Screen Shot 2014-04-08 at 9.26.25 AM
BusinessMedical InnovationsTechnology

Growth in Sales of Products in Cell Therapy and Tissue Engineering

April 12, 2014
Payer Trends Healthcare
BusinessFinanceGlobal HealthcareHealth ReformHospital AdministrationMedical DevicesMobile HealthPolicy & LawTechnology

Mid-Year Update: 4 Major Payer Trends

July 19, 2016
concierge medicine and obamacare physician shortages
BusinessNews

Concierge Medicine Will Get Massive Boost from Obamacare

December 22, 2012
business intelligence and medical billing
BusinessFinanceHospital AdministrationMedical RecordsOrthopaedics

Using Business Intelligence and Analytics for Orthopedic Billing

June 27, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?